Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atropine + fentanyl is a combination of two pharmaceutical agents commonly used in anesthesia and perioperative care. Atropine is an antimuscarinic agent that blocks the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. It is primarily used to reduce secretions and prevent bradycardia during surgical procedures. Fentanyl is a potent synthetic opioid analgesic that acts as an agonist at mu-opioid receptors in the central nervous system to provide profound pain relief and sedation. The combination may be used for premedication before anesthesia or for procedural sedation; atropine helps counteract opioid-induced bradycardia while fentanyl provides analgesia[1][2][5]. Both drugs are well-established pharmaceuticals with broad use in clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atropine + fentanyl.